MX2007008141A - Composicion farmaceutica de sustancias labiles en medio acido. - Google Patents

Composicion farmaceutica de sustancias labiles en medio acido.

Info

Publication number
MX2007008141A
MX2007008141A MX2007008141A MX2007008141A MX2007008141A MX 2007008141 A MX2007008141 A MX 2007008141A MX 2007008141 A MX2007008141 A MX 2007008141A MX 2007008141 A MX2007008141 A MX 2007008141A MX 2007008141 A MX2007008141 A MX 2007008141A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
acid labile
core
intermediate layer
labile substances
Prior art date
Application number
MX2007008141A
Other languages
English (en)
Inventor
Jyothi Gunupati
Suryakumar Jayanthi
Himadrisen
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of MX2007008141A publication Critical patent/MX2007008141A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Abstract

Una composicion farmaceutica para uso oral constituida por a) un nucleo que contiene una cantidad eficaz de un bencimidazol y un agente estabilizante organico que esta presente en una cantidad eficaz para estabilizar la composicion, b) una capa intermedia constituida por un polimero insoluble en agua y un estabilizante organico, y c) una capa exterior de recubrimiento enterico. El agente organico estabilizante esta presente en el nucleo en una proporcion aproximada de 1% a 10% en peso del nucleo y en la capa intermedia en una proporcion aproximada de 5% a 35% en peso de la capa intermedia.
MX2007008141A 2005-01-03 2006-01-03 Composicion farmaceutica de sustancias labiles en medio acido. MX2007008141A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1208MU2004 2005-01-03
PCT/IN2006/000004 WO2006085335A2 (en) 2005-01-03 2006-01-03 Pharmaceutical composition of acid labile substances

Publications (1)

Publication Number Publication Date
MX2007008141A true MX2007008141A (es) 2007-12-10

Family

ID=36645638

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007008141A MX2007008141A (es) 2005-01-03 2006-01-03 Composicion farmaceutica de sustancias labiles en medio acido.

Country Status (5)

Country Link
US (1) US20090208575A1 (es)
EP (1) EP1833469A2 (es)
AU (1) AU2006213439A1 (es)
MX (1) MX2007008141A (es)
WO (1) WO2006085335A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8802139B2 (en) 2003-06-26 2014-08-12 Intellipharmaceutics Corp. Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
US9561188B2 (en) * 2006-04-03 2017-02-07 Intellipharmaceutics Corporation Controlled release delivery device comprising an organosol coat
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
DE102006035549A1 (de) * 2006-07-27 2008-01-31 Evonik Röhm Gmbh Arzneiform mit mindestens zweischichtiger Trennschicht
ITMI20062290A1 (it) * 2006-11-28 2008-05-29 Monteres S R L Compresse stabili allo stoccaggio a base di derivati del benzimidazolo rivestite con film gastro-resistente
US20110052690A1 (en) * 2008-06-02 2011-03-03 Avi Avramoff Process for manufacture of a medicament with granulation and pan coating
CH699302B1 (de) * 2008-08-11 2012-03-15 Mepha Gmbh Orale pharmazeutische Formulierung für Omeprazol, enthaltend eine spezifische Trennschicht.
US20110150945A1 (en) * 2008-08-11 2011-06-23 Mepha Gmbh Oral pharmaceutical formulation for omeprazole comprising a specific separation layer
WO2010122583A2 (en) 2009-04-24 2010-10-28 Rubicon Research Private Limited Oral pharmaceutical compositions of acid labile substances
WO2011140446A2 (en) * 2010-05-06 2011-11-10 Dr. Reddy's Laboratories Ltd. Pharmaceutical formulations
US20130216617A1 (en) 2010-06-29 2013-08-22 Cadila Healthcare Limited Pharmaceutical compositions of (r)-lansoprazole
DE102010052847A1 (de) * 2010-11-29 2012-05-31 Temmler Werke Gmbh Verfahren zur Herstellung einer PPI-haltigen pharmazeutischen Zubereitung
AR089765A1 (es) 2012-01-23 2014-09-17 Bayer Oy Un sistema para el suministro de un farmaco
HUE053654T2 (hu) 2014-03-26 2021-07-28 Astex Therapeutics Ltd FGFR- és CMET-inhibitorok kombinációi a rák kezelésére
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1327010C (en) * 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
JPH0768125B2 (ja) * 1988-05-18 1995-07-26 エーザイ株式会社 酸不安定化合物の内服用製剤
US5232706A (en) * 1990-12-31 1993-08-03 Esteve Quimica, S.A. Oral pharmaceutical preparation containing omeprazol
YU48263B (sh) * 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
TW224049B (es) * 1991-12-31 1994-05-21 Sunkyong Ind Ltd
FR2692146B1 (fr) * 1992-06-16 1995-06-02 Ethypharm Sa Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention.
ES2094694B1 (es) * 1995-02-01 1997-12-16 Esteve Quimica Sa Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
CH687810A5 (de) * 1995-05-24 1997-02-28 Mepha Ag Pelletformulierung mit Omeprazol.
DE69631834T2 (de) * 1995-09-21 2005-02-10 Pharma Pass Ii Llc, Irvine Neues ein säureempfindliches benzimidazol enthaltendes mittel und verfahren zu dessen herstellung
DE19626045C2 (de) * 1996-06-28 1998-12-03 Klinge Co Chem Pharm Fab Stabile Arzneiform zur oralen Verabreichung, welche Omeprazol als aktiven Wirkstoff enthält, sowie Verfahren zur Herstellung derselben
JP2001524131A (ja) * 1997-05-09 2001-11-27 セイジ、ファーマスーティカルズ、インク 安定な経口医薬品剤形
CA2523218A1 (en) * 2003-04-22 2004-11-04 Dr. Reddy's Laboratories Limited Oral pharmaceutical formulations of acid-labile active ingredients and process for making same

Also Published As

Publication number Publication date
WO2006085335A3 (en) 2006-10-05
EP1833469A2 (en) 2007-09-19
US20090208575A1 (en) 2009-08-20
AU2006213439A1 (en) 2006-08-17
WO2006085335A2 (en) 2006-08-17

Similar Documents

Publication Publication Date Title
MX2007008141A (es) Composicion farmaceutica de sustancias labiles en medio acido.
BRPI0500704A (pt) composições de tratamento pessoal reidratáveis
EA018193B3 (ru) Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
WO2010037059A3 (en) Heteroaryl antagonists of prostaglandin d2 receptors
WO2010057118A3 (en) Heterocyclic antagonists of prostaglandin d2 receptors
BRPI0414581C1 (pt) composto, composição farmacêutica compreendendo o referido composto e uso do referido composto
WO2007122580A3 (en) Compositions of phenylephrine useful for treatment of respiratory illness
WO2010003127A3 (en) Antagonists of prostaglandin d2 receptors
WO2008057802A3 (en) Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
EA201100136A1 (ru) 2,4'-бипиридинилы в качестве ингибиторов протеинкиназы d, применимые для лечения сердечной недостаточности и рака
WO2009102893A3 (en) Cyclic diaryl ether compounds as antagonists of prostaglandin d2 receptors
WO2008092006A3 (en) Antimicrobial compositions
RS53056B (en) PHARMACEUTICAL PREPARATION CONTAINING (1S) -1,5-ANHYDRO-1- [5- (4-ETHOXYBENZYL) -2-METHOXY-4-METHYLPHENYL] -1-THI-D-GLUCITOL AND METFORMIN AND ITS USE IN THE TREATMENT OF DIABETES
MD20070267A (en) Gastroresistant pharmaceutical formulation containing rifaximin
DK2321321T3 (da) Triazolo [4,5-d]pyramidinderivater og anvendelse deraf som purinreceptorantagonister
ECSP077299A (es) Nuevas composiciones farmacéuticas que comprenden ácido 4-(4-(3-(4-cloro-3-trifluorometil-fenil)-ureido)-3-fluoro-fenoxi)-piridin-2-carboxílico para el tratamiento de trastornos hiperproliferativos
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
NZ585219A (en) Fast release solid formulation, preparation and use thereof
WO2010042652A3 (en) Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
DK2041133T3 (da) Derivater af imadazol [1,2-A] pyridine-2-carboxamider, fremstilling deraf og anvendelse deraf i terapeutik
RS53887B1 (en) TOPICAL APPLICATION FOR ACTINIC KERATOSIS
WO2006078659A8 (en) Stable prostaglandin-containing compositions
UY29169A1 (es) Derivados de 2-amido-4 feniltiazol, su preparacion y su aplicacion en terapeutica
AR057050A1 (es) Composicion de recubrimiento acuosa
BRPI0905687A2 (pt) "composto da fórmula i ou i', composição farmacêutica, método de tratamento de um paciente com uma doença, uso do composto"